WordNet
- (biology) any agency bringing about activation; a molecule that increases the activity of an enzyme or a protein that increases the production of a gene product in DNA transcription
- a cellular structure that is postulated to exist in order to mediate between a chemical agent that acts on nervous tissue and the physiological response
- the 10th letter of the Greek alphabet
- the 14th letter of the Roman alphabet (同)n
PrepTutorEJDIC
- 《所有・所属》…『の』,…のものである,…に属する・《材料・要素》…『でできた』,から成る・《部分》…『の』[『中の』] ・《数量・単位・種類を表す名詞に付いて》…の・《原因・動機》…『で』,のために(because of) ・《主格関係》…『の』,による,によって・《目的格関係》…『を』,の・《同格関係》…『という』・《関係・関連》…『についての』[『の』],の点で・《抽象名詞などと共に》…の[性質をもつ] ・《『It is』+『形』+『of』+『名』+『to』 doの形で,ofの後の名詞を意味上の主語として》・《分離》…『から』・《起原・出所》…『から』[『の』](out of) ・《『名』+『of』+『a』(『an』)+『名』の形で》…のような・《『名』+『of』+『mine』(『yours, his』など独立所有格)の形で》…の…・《時》(1)《副詞句を作って》…に《形容詞句を作って》…の・《時刻》《米》…前(to,《米》before)
- =sense organ / 受信装置
- カッパ(ギリシア語アルファベットの第10字Κ,k;英語の『K,k』に相当)
- nitrogenの化学記号
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. IL-1、IL-6、およびRANKLを抑制する生物学的製剤の関節リウマチにおける
ランダム化臨床試験 randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit il 1 il 6 and rankl - 2. 骨の巨大細胞腫瘍 giant cell tumor of bone
- 3. 多発性骨髄腫の病理生物学 pathobiology of multiple myeloma
- 4. 骨転移の機序 mechanisms of bone metastases
- 5. Osteoclast inhibitors in the management of bone metastases from breast cancer
English Journal
- Effects of icariin on the regulation of the OPG‑RANKL‑RANK system are mediated through the MAPK pathways in IL‑1β‑stimulated human SW1353 chondrosarcoma cells.
- Wang Z1, Ding L1, Zhang S1, Jiang T2, Yang Y3, Li R1.
- International journal of molecular medicine.Int J Mol Med.2014 Dec;34(6):1720-6. doi: 10.3892/ijmm.2014.1952. Epub 2014 Sep 30.
- Arthrodial cartilage degradation and subchondral bone remodeling comprise the most predominant pathological changes in osteoarthritis (OA). Moreover, accumulating evidence indicates that the abnormal expression of osteoprotegerin (OPG), receptor activator of nuclear factor kappa-B ligand (RANKL) a
- PMID 25270538
- Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
- Park HS1, Lee A, Chae BJ, Bae JS, Song BJ, Jung SS.
- Journal of surgical oncology.J Surg Oncol.2014 Dec;110(7):807-12. doi: 10.1002/jso.23737. Epub 2014 Aug 11.
- PURPOSE: Receptor activator of nuclear factor kappa-B and its ligand (RANK/RANKL) and Osteoprotegerin (OPG) are key molecules for regulating osteoclastic activity in bone. However, little is known about the role of RANK-related molecules in breast cancer prognosis. We aimed to evaluate RANK, RANKL,
- PMID 25111682
- Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
- Li X1, Liu Y2, Wu B3, Dong Z1, Wang Y1, Lu J1, Shi P1, Bai W4, Wang Z1.
- Oncology reports.Oncol Rep.2014 Dec;32(6):2605-11. doi: 10.3892/or.2014.3511. Epub 2014 Sep 23.
- Receptor activator of NF-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) are key regulators of bone metabolism under both normal and pathological conditions, including prostate cancer (PCa) bone metastases. However, little is known concerning the expression and function of these regulators
- PMID 25333856
Japanese Journal
- Macrophage-elicited osteoclastogenesis in response to bacterial stimulation requires Toll-like receptor 2-dependent tumor necrosis factor-alpha production.
- Ukai Takashi,Yumoto Hiromichi,Gibson Frank C,Genco Caroline Attardo
- Infection and immunity 76(2), 812-819, 2008-02
- … The receptor activator of NF-kappaB ligand (RANKL) and the proinflammatory cytokines are believed to play important roles in osteoclastogenesis. …
- NAID 120001885811
- Inhibitory Effects of Platelet-rich Plasma on Osteoclast Differentiation in RAW264.7 Cells(International Symposium of Maxillofacial and Oral Regenerative Biology in Okayama 2005)
- Kikuchi Hirotaka,Duan Jianmin,Kobayashi Kenji,Suda Tomoyo,Satho Masashi,Sugi Yuki,Katayama Tadashi,Nishikawa Hirofumi
- Journal of
- … Platelet-rich plasma (PRP) is an autologous source of platelet-derived growth factors, and has been used successfully in oral surgery repair and in the placement of osseointegrated implants. … However, little is known about the underlying release mechanisms of these factors or the manner in which inhibition of osteoclastic cells is regulated. …
- NAID 110005853474
Related Links
- Ligand for receptor activator of NF-kappaB US 20020169117 A1 要約書 Isolated ligands, DNAs encoding such ligands, and pharmaceutical compositions made therefrom, are disclosed. The isolated ligands can be used to regulate ...
- 1. J Biol Chem. 2003 Nov 14;278(46):46171-8. Epub 2003 Sep 2. Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells. Srivastava S, Matsuda M, Hou Z, Bailey JP, Kitazawa R, Herbst MP ...
Related Pictures
★リンクテーブル★
| リンク元 | 「破骨細胞分化因子」「RANKL」「osteoclast differentiation factor」「NFκB活性化受容体リガンド」 |
| 関連記事 | 「activator」「N」「NF」「kappa」 |
「破骨細胞分化因子」
- 英
- osteoclast differentiation factor、receptor activator of NF-kappaB ligand、RANKL
- 関
- 破骨細胞分化抑制因子リガンド、NFκB活性化受容体リガンド、ランクリガンド
-RANKL
- 同
- receptor activator for nuclear factor kB ligand
「RANKL」
- 同
- receptor activator for nuclear factor kB ligand
「osteoclast differentiation factor」
「NFκB活性化受容体リガンド」
「activator」
- n.
「N」
- アスパラギン asparagine
- 窒素(原子、分子)